Background. Depot GnRH analogs represent the treatment of choice for central precocious puberty (CPP). Few data are available on pubertal suppression for the newer 3-month formulations. In addition, comparison between the monthly and quarterly tripotorelin depot is lacking. Aim: To assess the efficacy on pituitary and gonadal suppression of triptorelin 11.25 mg/3 months in girls with CPP and to compare the new formulation with triptorelin 3.75 mg/28 days. Patients and Methods: Thirty-five girls with clinical and endocrine diagnosis of CPP (puberty onset <8 yr). All but three girls were White Italians (Indian in = 2; Hungarian, n = 1). The girls were admitted to treatment with triptorelin depot (IPSEN-Biotech, Milan, Italy) in quarterly (group A: n = 15) or monthly (group B: n = 20) formulation. Patients were re-evaluated after 3 and 6 months of therapy. Results: In both groups, peak LH values (IU/l) were significantly decreased (p <0.005) at 3 (group A 0.8 +/- 0.4; group B 1.0 +/- 0.4) and 6 months (group A 0.8 +/- 0.4; group B 1.0 +/- 0.3) in comparison with baseline values (group A 22.5 +/- 16.1; group B 24.0 +/- 16.7); no differences were found between peak LH values at 3 and 6 months. Baseline LH values (IU/l) also decreased (group A: 0 mo 1.9 +/- 1.7, 3 mo 0.3 +/- 0.2, 6 mo 0.3 +/- 0.2; group B: 0 mo 2.2 +/- 2.1, 3 mo 0.4 +/- 0.3, 6 mo 0.4 +/- 0.2) No LH peak levels above the threshold for complete suppression were detected in either group. Basal and peak FSH as well as basal 17 beta-estradiol concentrations also showed a significant decrease at 3 months in both groups and stabilized thereafter. There were no significant differences between the patients treated by the quarterly or monthly preparation. No side effects were recorded. Conclusion: Triptorelin 11.25 mg/3 months is able to suppress the LH peak to prepubertal values in 100% of examined patients at 3 and 6 months of therapy. In addition, the triptorelin 11.25 mg/3 months formulation was equally effective in suppressing pituitary and gonadal secretion as the 3.75 mg/28 days preparation, suggesting that the new formulation is as effective as the monthly formulation, and that it can be the initial treatment in girls with CPP.

Central precocious puberty: Short-term comparative data of treatment with monthly or long-acting three months depot triptorelin

SAGGESE, GIUSEPPE
2007

Abstract

Background. Depot GnRH analogs represent the treatment of choice for central precocious puberty (CPP). Few data are available on pubertal suppression for the newer 3-month formulations. In addition, comparison between the monthly and quarterly tripotorelin depot is lacking. Aim: To assess the efficacy on pituitary and gonadal suppression of triptorelin 11.25 mg/3 months in girls with CPP and to compare the new formulation with triptorelin 3.75 mg/28 days. Patients and Methods: Thirty-five girls with clinical and endocrine diagnosis of CPP (puberty onset <8 yr). All but three girls were White Italians (Indian in = 2; Hungarian, n = 1). The girls were admitted to treatment with triptorelin depot (IPSEN-Biotech, Milan, Italy) in quarterly (group A: n = 15) or monthly (group B: n = 20) formulation. Patients were re-evaluated after 3 and 6 months of therapy. Results: In both groups, peak LH values (IU/l) were significantly decreased (p <0.005) at 3 (group A 0.8 +/- 0.4; group B 1.0 +/- 0.4) and 6 months (group A 0.8 +/- 0.4; group B 1.0 +/- 0.3) in comparison with baseline values (group A 22.5 +/- 16.1; group B 24.0 +/- 16.7); no differences were found between peak LH values at 3 and 6 months. Baseline LH values (IU/l) also decreased (group A: 0 mo 1.9 +/- 1.7, 3 mo 0.3 +/- 0.2, 6 mo 0.3 +/- 0.2; group B: 0 mo 2.2 +/- 2.1, 3 mo 0.4 +/- 0.3, 6 mo 0.4 +/- 0.2) No LH peak levels above the threshold for complete suppression were detected in either group. Basal and peak FSH as well as basal 17 beta-estradiol concentrations also showed a significant decrease at 3 months in both groups and stabilized thereafter. There were no significant differences between the patients treated by the quarterly or monthly preparation. No side effects were recorded. Conclusion: Triptorelin 11.25 mg/3 months is able to suppress the LH peak to prepubertal values in 100% of examined patients at 3 and 6 months of therapy. In addition, the triptorelin 11.25 mg/3 months formulation was equally effective in suppressing pituitary and gonadal secretion as the 3.75 mg/28 days preparation, suggesting that the new formulation is as effective as the monthly formulation, and that it can be the initial treatment in girls with CPP.
Bertelloni, S; Cassio, A; Arrigo, T; Wasniewska, M; Galluzzi, F; Einaudi, S; Cappa, M; Chiumello, G; Bal, M; Losi, S; Baroncelli, Gi; Saggese, Giuseppe
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11568/116421
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 6
social impact